WHY IT MATTERS: As federal rescheduling moves forward, organizations that center both clinical evidence and patient experience could directly shape whether patients gain broader, safer, and more affordable access to cannabinoid therapies. CLINICAL OVERVIEW: A newly formed cannabis medicine group is working to ensure that federal policy discussions around cannabinoid therapy are rooted in scientific evidence and shaped by real patient perspectives. This effort comes at a critical moment as rescheduling conversations advance at the federal level, creating an opening to influence how cannabis is regulated, researched, and integrated into clinical care.
5 Reasons CBD CBG Topicals For Eczema Care is Amazing
A recent pilot study suggests that a CBD CBG topical for eczema might offer more than a passing fad. With significant improvements in hydration, barrier repair, and inflammation, cannabinoids are making a case for inclusion in dermatologic care. While it’s far from a clinical revolution, the data are compelling enough to earn a deeper look—and maybe a patch test.
7 Crucial Facts About Medical Cannabis Safety for 2024
Medical cannabis is showing promise in treating a variety of symptoms without compromising cognitive health, but understanding its long-term safety is key. A recent study reveals that light to moderate use of cannabis may not impair cognition over one year, but issues like tolerance and dose escalation remain concerns for the future.